Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
Hemasphere|December 28, 2020
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3Christian Winther Eskelund, Kostas Dimopoulos, Arne Kolstad, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2006
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantationDaniel H Fowler, Jeanne Odom, Seth M Steinberg, et al.
Blood|July 16, 2008
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupChristian H Geisler, Arne Kolstad, Anna Laurell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2017
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 YearsArne Kolstad, Lone Bredo Pedersen, Christian W Eskelund, et al.
British Journal of Haematology|March 7, 2022
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccinationJon Riise, Saskia Meyer, Isaac Blaas, et al.
Blood Advances|September 11, 2023
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphomaIvana Spasevska, Ankush Sharma, Chloé B Steen, et al.
Blood|July 28, 2011
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 casesAnastasia Hadzidimitriou, Andreas Agathangelidis, Nikos Darzentas, et al.
Blood|March 22, 2014
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphomaArne Kolstad, Anna Laurell, Mats Jerkeman, et al.
British Journal of Haematology|July 6, 2016
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateauChristian W Eskelund, Arne Kolstad, Mats Jerkeman, et al.
Pageof 10